MILAN (Reuters) -The possible introduction of tariffs in the U.S. on pharmaceutical imports won't stop Italy's Chiesi Group from supplying patients in need of its products, CEO Giuseppe Accogli told ...

MILAN, April 16 (Reuters) - The possible introduction of tariffs in the U.S. on pharmaceutical imports won't stop Italy's Chiesi Group from supplying patients in need of its products, CEO Giuseppe ...

Chiesi is hoping real world evidence will show its latest COPD triple therapy can help cut hospital admissions for the disease. Trimbow (beclometasone+formoterol+glycopyrronium) combines an ...

Chiesi GRD has an initial focus in developing therapies for lysosomal storage disorders (LSDs), including Fabry disease, as well as other rare diseases in haematology and opthalmology indications.

Founding Members Chiesi, BIAL Lead Initial Funding; Landmark Bio, Uncommon Cures Join Clinical Development Network; DVLP Medicines, Vibe Bio to Provide Integrated AI-based Solutions BOSTON--(BUSINESS ...

A statement from the commission said Novo Nordisk, Novartis, Fresenius, Sanofi, Bayer, Gedeon Richter and Ipsen Chiesi attended the call. Further, the statement said the industry raised "strong ...

A statement from the commission said Novo Nordisk, Novartis, Fresenius, Sanofi, Bayer, Gedeon Richter and Ipsen Chiesi attended the call. Further, the statement said the industry raised "strong ...

The overall incidence of colorectal cancer (CRC) in the United Kingdom plateaued at 67.4 per 100,000 person-years from 2000 to 2021, with slight improvements observed in overall survival ...